Quick Answer
Harmony Biosciences Holdings, Inc. reported R&D Expense of $189.59 million for fiscal year 2025.
Harmony Biosciences Holdings, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $189.59M | +30.0% |
| 2024 | $145.82M | +91.7% |
| 2023 | $76.06M | +7.3% |
| 2022 | $70.89M | +133.4% |
| 2021 | $30.37M | +56.1% |
| 2020 | $19.45M | -72.1% |
| 2019 | $69.59M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $54.96M | +116.5% | +9.6% |
| June 30, 2025 | $50.16M | -21.1% | +45.2% |
| March 31, 2025 | $34.54M | +55.7% | +36.1% |
| September 30, 2024 | $25.39M | +45.1% | -60.1% |
| June 30, 2024 | $63.58M | +324.8% | +186.6% |
| March 31, 2024 | $22.19M | +67.0% | +26.8% |
| September 30, 2023 | $17.50M | -56.8% | +16.9% |
| June 30, 2023 | $14.97M | +18.2% | +12.6% |
- Harmony Biosciences Holdings, Inc. showed an increase of +30.0% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Harmony Biosciences Holdings, Inc.’s r&d expense has grown by 172.4% (from $69.59 million to $189.59 million).
- The most recent figure is from Harmony Biosciences Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: